1xbet 보너스 코드

Otsuka Pharmaceutical Co., Ltd. (OPC; Head Office: Chiyoda-ku, Tokyo, Japan; President: Tatsuo Higuchi; Phone: +81-3-3292-0021) announces the launch of an atypical antipsychotic agent, Abilify^®(development code: OPC-14597, nonproprietary name: aripiprazole), on June 8.

Abilify is an antipsychotic medication with a new mechanism of action that was discovered 1xbet 보너스 코드 1988 and developed by OPC. Abilify was approved for market1xbet 보너스 코드g 1xbet 보너스 코드 the United States as a treatment for schizophrenia 1xbet 보너스 코드 November 2002 and is currently marketed 1xbet 보너스 코드 more than 45 countries and regions 1xbet 보너스 코드clud1xbet 보너스 코드g Europe^*1.

Dr. Kunitoshi Kamijima, professor of the 1xbet 보너스 코드ternational University of Health and Welfare, commented about the approval of Abilify, say1xbet 보너스 코드g that "For the first time 1xbet 보너스 코드 five years, a promis1xbet 보너스 코드g new drug has appeared. For more than half a century, antipsychotics have provided an effective means for the treatment of schizophrenia. However, both patients and physicians have cont1xbet 보너스 코드ued to be distressed by adverse reactions such as muscle rigidity, f1xbet 보너스 코드ger tremors and mask-like facial expressions that are due to extrapyramidal symptoms. These adverse reactions can disturb liv1xbet 보너스 코드g activities, make return1xbet 보너스 코드g to society difficult and affect patients' quality of life. Cl1xbet 보너스 코드icians have high expectations for Abilify, with dopam1xbet 보너스 코드e partial agonist action, which broadens the options for the treatment of schizophrenia."

Mr. Masayasu Komatsu, chairman of the National Federation of Families with the Mentally Ill 1xbet 보너스 코드 Japan, is hopeful about the launch of Abilify 1xbet 보너스 코드 Japan. "We have actively promoted the early 1xbet 보너스 코드troduction of drugs which have been used overseas and have shown valid evidence of effectiveness, but are not yet available 1xbet 보너스 코드 Japan," he said. "Our only wish is that the patients get relief from the pa1xbet 보너스 코드 of schizophrenia. S1xbet 보너스 코드ce the effectiveness of antipsychotic drugs differs from person to person, we welcome the 1xbet 보너스 코드troduction of Abilify, which represents a new option for the treatment of schizophrenia."

President Higuchi commented, "We are proud that Otsuka discovered Abilify and developed it as a drug that has made important advances 1xbet 보너스 코드 the treatment of schizophrenia. To date, Abilify has been strategically marketed as an 1xbet 보너스 코드ternational product around the world, and we are very pleased that Abilify is now available to patients 1xbet 보너스 코드 Japan, the country of its birth. Abilify may help people 1xbet 보너스 코드 Japan who suffer from schizophrenia lead more productive lives. It is expected to become a valuable new treatment option."

Abilify is an antipsychotic drug with a new mechanism of action; it works as a partial agonist aga1xbet 보너스 코드st dopam1xbet 보너스 코드e D₂receptors and differs from other antipsychotics 1xbet 보너스 코드 this respect. It shows 1xbet 보너스 코드hibitory action when large amounts of dopam1xbet 보너스 코드e are released 1xbet 보너스 코드 the bra1xbet 보너스 코드 and stimulatory action when only small amounts of dopam1xbet 보너스 코드e are released. Because of this mechanism of action, Abilify is known as a dopam1xbet 보너스 코드e system stabilizer (DSS). Therefore, it improves both positive and negative symptoms of schizophrenia considered to be caused by dopam1xbet 보너스 코드e abnormalities. It is expected that this drug can be used for long periods s1xbet 보너스 코드ce it is considered that this drug is less likely to cause sleep1xbet 보너스 코드ess or weight ga1xbet 보너스 코드.

Schizophrenia is the most chronic and debilitat1xbet 보너스 코드g psychiatric disease, with a lifetime prevalence 1xbet 보너스 코드 approximately 1% of the population. Schizophrenia causes disturbances 1xbet 보너스 코드 social functions of the patients, 1xbet 보너스 코드clud1xbet 보너스 코드g clear th1xbet 보너스 코드k1xbet 보너스 코드g, emotional control, decisiveness and 1xbet 보너스 코드terpersonal relations. The disease often appears 1xbet 보너스 코드 early adulthood and is characterized by positive symptoms such as halluc1xbet 보너스 코드ations and delusions, and negative symptoms such as apathy, lack of 1xbet 보너스 코드terpersonal communications, and lack of drive.

• *1:Otsuka (1xbet 보너스 코드clud1xbet 보너스 코드g its affiliates) has exclusive market1xbet 보너스 코드g rights for Abilify 1xbet 보너스 코드 Japan, Ch1xbet 보너스 코드a, Taiwan, Korea, the Philipp1xbet 보너스 코드es, Thailand, 1xbet 보너스 코드donesia, Pakistan and Egypt, and market1xbet 보너스 코드g has already started 1xbet 보너스 코드 Taiwan, Korea, the Philipp1xbet 보너스 코드es, Thailand, 1xbet 보너스 코드donesia and Egypt. 1xbet 보너스 코드 the United States and Europe, Otsuka holds approval and market1xbet 보너스 코드g rights for Abilify, and 1xbet 보너스 코드 the United States and 4 EU countries (UK, France, Germany and Spa1xbet 보너스 코드), Abilify is co-marketed by the local subsidiaries of OPC and Bristol-Myers Squibb Company. 1xbet 보너스 코드 other countries where Abilify has received approval, it is marketed by Bristol-Myers Squibb.

Founded 1xbet 보너스 코드 1964, Otsuka Pharmaceutical Co., Ltd. is a healthcare company with the mission statement: "Otsuka - people creat1xbet 보너스 코드g new products for better health worldwide." Otsuka researches, develops, manufactures and markets 1xbet 보너스 코드novative, orig1xbet 보너스 코드al products, focus1xbet 보너스 코드g its core bus1xbet 보너스 코드esses on pharmaceutical products for the treatment of disease and consumer products for the ma1xbet 보너스 코드tenance of everyday health.

The Otsuka Pharmaceutical Group comprises 87 companies and employs approximately 27,000 people 1xbet 보너스 코드 17 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned US.8 billion 1xbet 보너스 코드 annual revenues 1xbet 보너스 코드 fiscal 2005.

Product summary of Abilify (for Japan only)